Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact
Open Access
- 20 May 2021
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 11 (5) , 911
Abstract
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a catastrophic complication of one of the most common and devastating autoimmune diseases. Once diagnosed, it becomes the leading cause of mortality among this patient population. Screening modalities and risk assessments have been designed and validated by various organizations and societies in order to identify patients early in their disease course and promptly refer them to expert centers for a hemodynamic assessment and formal diagnosis. Moreover, several large multicenter clinical trials have now included patients with SSc-PAH to assess their response to therapy. Despite an improved understanding of the condition and significant advances in supportive and targeted therapy, outcomes have remained far from optimal. Therefore, rigorous phenotyping and search for novel therapies are desperately needed for this devastating condition.Keywords
Funding Information
- National Institutes of Health (HL114910)
This publication has 114 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Meta‐AnalysisArthritis & Rheumatism, 2013
- ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centreEuropean Respiratory Journal, 2011
- Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study PopulationThe Journal of Rheumatology, 2011
- Right and Left Ventricular Myocardial Perfusion Reserves Correlate with Right Ventricular Function and Pulmonary Hemodynamics in Patients with Pulmonary Arterial HypertensionRadiology, 2011
- Hemodynamic Predictors of Survival in Scleroderma-related Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patientsAnnals of the Rheumatic Diseases, 2009
- Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie studyRheumatology, 2008
- Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseasesAnnals of the Rheumatic Diseases, 2008
- Hyponatremia Predicts Right Heart Failure and Poor Survival in Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2008